In direct-compression tablet manufacturing, pravastatin sodium is specified at label strengths of 10 mg, 20 mg, 40 mg, and 80 mg. The blend is prepared without granulation fluid because the sodium salt is freely soluble in water and moisture exposure during aqueous granulation promotes equilibrium formation of the pharmacologically inactive lactone. In a representative 120 mg core for 10 mg strength, the API fraction is 8.3% w/w; at a 500 mg core for 80 mg strength, the API fraction is 16.0% w/w. The dry-mix process begins with passing pravastatin sodium and microcrystalline cellulose through a 20-mesh screen, followed by blending in a bin blender at 12 rpm for 15 min. Croscarmellose sodium at 3.0–4.0% w/w is added as disintegrant, and lactose monohydrate is used as a water-soluble filler. Lubrication is performed with magnesium stearate at 0.5–1.0% w/w for 3 min; batches exceeding 1.5% w/w magnesium stearate are rejected because the hydrophobic lubricant film delays tablet disintegration and produces dissolution lag. Compression is carried out on a rotary tablet press using 10 mm round flat-faced beveled tooling at 8–15 kN; precompression is set at 3–5 kN to expel air. Tablet hardness is held at 50–100 N, and friability is monitored per USP <1216> at NMT 1.0%. The major field failure mode is sticking and picking when residual moisture exceeds 2.0% by USP <921>; therefore excipients are preconditioned at ≤ 40% RH. Release testing includes assay by HPLC per USP <621> with acceptance 90.0–110.0%, content uniformity per USP <905> with acceptance value ≤ 15.0, and dissolution per USP <711> Apparatus II at 50 rpm in 900 mL deaerated water with Q not less than 75% at 30 min where the monograph permits. Related substances are controlled under ICH Q3B(R2); unspecified impurities are limited to ≤ 0.10%. Terminal finished products are white to off-white film-coated tablets of 10 mg, 20 mg, 40 mg, and 80 mg, packaged in HDPE bottles with desiccant. The formulation is incompatible with acidic fillers such as citric acid or ascorbic acid because the resulting local pH below 5.0 accelerates lactone formation.

When Does Intragranular pH Control Become the Limiting Step in Wet Granulation of Pravastatin Sodium?

The acid-catalyzed lactonization of pravastatin sodium imposes a narrow pH working window during wet granulation. Granulating fluids are prepared with purified water adjusted to pH 7.0–8.0 using sodium hydroxide or a sodium phosphate buffer; a granule pH below 5.0 during wet massing or drying increases the non-pharmacologically active pravastatin lactone degradation product. The formulation addition ratio for wet-granulated tablets is generally 5.0–12.0% w/w pravastatin sodium in the dried granule mass, corresponding to label strengths of 10–80 mg at core weights of 200–800 mg. Hypromellose E5 at 2.0% w/w of the granulation mass is used as binder, and sodium bicarbonate at 1.0–2.0% w/w is dispersed in the dry powder before the aqueous granulating fluid is added so that the granule pH remains above 7.0 until drying is complete. The downstream process uses a high-shear granulator with impeller speed 200–400 rpm and chopper speed 1,000–1,500 rpm; wet massing time is 90–180 s. The wet mass is milled through a 6.0 mm screen and dried in a fluid-bed dryer with inlet air at ≤ 40°C to a product moisture endpoint of 1.0–2.0%. Drying above this window is avoided because published stability data for pravastatin sodium show temperature- and moisture-dependent degradation. Dried granules are milled through an 800 μm screen and lubricated with sodium stearyl fumarate at 0.5–1.0% w/w, chosen to avoid the dissolution lag associated with magnesium stearate in hygroscopic systems. Release testing follows the oral solid dosage matrix in Table 1; assay by HPLC per USP <621> is 90.0–110.0%, content uniformity by USP <905> is ≤ 15.0, dissolution by USP <711> Apparatus II at 50 rpm is Q ≥ 75% at 30 min, and unspecified impurities under ICH Q3B(R2) are ≤ 0.10%. Terminal finished forms are film-coated tablets of 10 mg, 20 mg, 40 mg, and 80 mg for oral administration. This route is selected when direct-compression blends exhibit flow-induced segregation in high-speed tablet presses, especially at API fractions below 8.0% w/w, or when the API must be embedded in a pH-buffered intragranular matrix to resist acid contact in the gastrointestinal fluid.

Because capsule filling of pravastatin sodium is sensitive to excipient moisture and lubricant type, the process is designed around low-moisture dry granulation rather than direct encapsulation of the uncompacted powder. The API addition ratio in hard gelatin or HPMC capsule formulations is commonly 11.1% w/w for a 20 mg strength at a fill mass of 180 mg, and 16.0% w/w for a 40 mg strength at a fill mass of 250 mg. Microcrystalline cellulose and lactose monohydrate are pre-dried at ≤ 40% RH until moisture by USP <921> is ≤ 2.0%; crospovidone at 2.0–3.0% w/w is included as a disintegrant. The pre-blend is compacted on a roller compactor with roll pressure 20–30 kN/cm, granulated through an 800 μm screen, and lubricated with sodium stearyl fumarate at 0.5–1.0% w/w; magnesium stearate above 1.0% w/w is excluded because its hydrophobic surface film delays capsule disintegration. The granulate is filled on a dosator-pin capsule machine with fill weight control at ± 3.0%, using size 3 hard gelatin capsules for 20 mg strength and size 1 capsules for 40 mg. Shell water content is maintained at 13–16% w/w for gelatin and 4–6% w/w for HPMC to avoid embrittlement or deformation. Batch release is governed by 21 CFR 211.165; in-process blend uniformity sampling follows 21 CFR 211.110. Dissolution is determined by USP <711> Apparatus II at 50 rpm in 900 mL deaerated water; content uniformity follows USP <905> with ≤ 15.0. Terminal finished products are oral capsule dosage forms of 10 mg, 20 mg, and 40 mg, packed in HDPE bottles with child-resistant closures. This route is preferred when a rapid-disintegrating oral form is required and when the drug product must avoid film-coating solvents or tablet compression defects associated with high filler loading.

pH-Controlled Lyophilization and Sterile Filtration Boundaries for Injectable Pravastatin Sodium

Parenteral pravastatin sodium has not reached the same level of pharmacopoeial harmonization as oral solid dosage forms; published data for this specific configuration is limited, so any injectable manufacturing file should be treated as development-stage. Where configured, the formulation addition ratio is fixed at 5.0 mg pravastatin sodium per vial with 100 mg mannitol as a crystalline bulking agent, giving an API fraction of 4.8% w/w of the lyophilized cake. The solution is prepared in Water for Injection at 15–25°C, adjusted with sodium hydroxide to pH 7.4–8.0; excursions below pH 5.0 are considered incompatible because the sodium salt equilibrates to the lactone form. The bulk solution is sterile-filtered through a 0.22 μm PVDF filter under nitrogen pressure, with pre- and post-use diffusional flow integrity testing; the filter is validated with Brevundimonas diminuta at 10⁷ CFU/cm². The solution is filled into 5 mL Type I borosilicate glass vials meeting USP <660> at 3.0–3.2 mL per vial, then partially stoppered. Lyophilization is required because pravastatin sodium in aqueous solution is heat-sensitive and cannot be terminal-steam sterilized. The lyophilization cycle uses freezing at -40°C for 240 min, primary drying at -20°C and chamber pressure 0.20 mbar for 48 h, and secondary drying at 25°C and 0.10 mbar to a cake water content NMT 1.0% by USP <921>. The finished lyophilized cake is intended for reconstitution with 5.0 mL Sterile Water for Injection before intravenous infusion. Quality release follows USP <1> for injections, USP <71> sterility, USP <85> bacterial endotoxins, and USP <788> particulate matter; the endotoxin acceptance limit is calculated for the intravenous dose under USP <85>. Elemental impurity risk assessment is performed against ICH Q3D(R2), with particular attention to Class 1 elements from vial glass and stopper extractables. The terminal product is a sterile lyophilized powder for reconstitution, not a ready-to-use infusion.

If a Fixed-Dose Combination with Fenofibrate Is Manufactured, Then Bilayer Compression Requires Separate Granulation Streams

Fixed-dose combination tablets containing pravastatin sodium and fenofibrate exhibit incompatible processing requirements: fenofibrate is practically insoluble and requires surfactant-assisted granulation, whereas pravastatin sodium requires pH-buffered dry granulation. The reference strength pair of 40 mg pravastatin sodium with 160 mg fenofibrate is manufactured in a 600 mg bilayer tablet core, corresponding to pravastatin sodium at 6.7% w/w and fenofibrate at 26.7% w/w of the total core mass. The fenofibrate layer is prepared by micronizing the API to a D90 of ≤ 10 μm; granulation is performed with sodium lauryl sulfate at 0.5–1.0% w/w, lactose monohydrate, and crospovidone, using an aqueous granulating fluid at pH 5.5–7.0. The pravastatin layer uses the dry granulation route described above: microcrystalline cellulose, croscarmellose sodium at 2.0% w/w, dibasic calcium phosphate dihydrate at 10.0% w/w as a buffering filler, and sodium stearyl fumarate at 0.5–1.0% w/w. The two granulations are compressed on a bilayer rotary press with first-layer tamping force 2–4 kN and main compression force 10–18 kN; the press must be equipped with automatic weight control for both layers to prevent layer separation and weight drift. Dissolution testing follows USP <711>; because fenofibrate is released from a separate layer, the dissolution medium and paddle speed are established from the fenofibrate monograph and usually include a surfactant to maintain sink conditions. Content uniformity is assessed by USP <905> with ≤ 15.0, impurities by ICH Q3B(R2), and fixed-dose combination justification by FDA 21 CFR 300.50. Terminal finished products are film-coated bilayer tablets for oral administration, not intended for splitting or dose titration because the two layers are not uniformly distributed across the tablet. The process boundary is defined by compression force: main compression above 18 kN can induce layer separation due to elastic recovery differences between the fenofibrate and pravastatin layers.

Granulated oral presentations of pravastatin sodium for sachet reconstitution are formulated at a lower API loading than tablets because the entire sachet contents are swallowed as a powder or dispersed in water. The addition ratio for a 20 mg sachet is typically 2.0% w/w when the filled granule mass is 1.0 g; a 40 mg sachet may be filled to 2.0 g at the same 2.0% w/w loading. The granulation is built on a mannitol carrier with hypromellose E5 binder at 2.0% w/w, sodium bicarbonate at 1.0–2.0% w/w as a pH buffer, and a flavour fraction of 0.2% w/w. The process is wet granulation in a low-shear mixer, with the granulating fluid adjusted to pH 7.0–8.0; after wet massing, the granules are dried in a fluid-bed dryer at inlet air ≤ 40°C to a moisture endpoint of 1.0–2.0%, milled through a 500 μm screen, and filled into sachets on a vertical form-fill-seal line with fill weight control at ± 2.0%. The critical defect is dose proportioning drift caused by API migration to the fines during the filling process; therefore the 500 μm milled granule is blended with the fines generated below 150 μm in a controlled ratio, and blend uniformity is verified under 21 CFR 211.110. Release testing for single-dose sachets includes uniformity of mass per Ph. Eur 2.9.5, water content by USP <921>, dissolution for the reconstituted suspension using USP <711> Apparatus II at 75 rpm in 900 mL deaerated water, and degradation products under ICH Q3B(R2). Terminal finished products are unit-dose sachets or stick packs containing granules for oral suspension, used in settings where tablet swallowing is not acceptable. The product must be packaged in moisture-impermeable laminate because pravastatin sodium granules absorb atmospheric moisture and form lactone; desiccant is not a substitute for a cold-form or high-barrier foil structure.